Paper Details

  1. Home
  2. Paper Details

Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.

Author: DesarIngrid M E, JansmanFrank G A, KrensStefanie D, MulderSasja F, UijenMaike J M, van BoxtelWim, van ErpNielka P, van HerpenCarla M L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explored the cabozantinib exposure in patients with different tumor types, finding that salivary gland carcinoma patients had significantly higher cabozantinib exposure at the starting dose compared to renal cell carcinoma patients.
Paper Details　
Original Abstract of the Article :
Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has been observed in renal cell carcinoma patients (RCC) with a cabozantinib exposure greater than 750 μg/L...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291492/

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A Balancing Act of Efficacy and Toxicity

Cabozantinib is a powerful drug used to fight cancer, but its use is often hindered by side effects. This study takes us on a journey through the complex world of drug dosage and its impact on both efficacy and toxicity.

The researchers compared the levels of cabozantinib in the blood of patients with renal cell carcinoma (RCC) and salivary gland carcinoma (SGC). They found that patients with SGC had higher levels of cabozantinib at the standard starting dose, leading to more frequent side effects.

Finding the Sweet Spot in Drug Dosage

This study highlights the importance of personalized medicine, where drug dosages are tailored to individual needs and responses. While higher levels of cabozantinib may lead to better tumor control in some patients, they also increase the risk of side effects. The challenge lies in finding the “sweet spot” where the drug is effective without causing excessive harm.

Navigating the Desert of Side Effects

This research underscores the need for careful monitoring of cabozantinib dosage and close attention to individual patient responses. Working with healthcare professionals to manage potential side effects and optimize treatment is crucial. Remember, the journey through cancer treatment is often a desert of uncertainty, but finding the right balance of efficacy and toxicity can help us find our way to a healthier destination.

Dr.Camel's Conclusion

This study emphasizes the need for personalized medicine in cancer treatment. Finding the right balance of efficacy and toxicity for cabozantinib is a delicate dance, requiring close monitoring and careful consideration of individual patient responses.

Date :
  1. Date Completed 2021-12-20
  2. Date Revised 2022-07-21
Further Info :

Pubmed ID

34494665

DOI: Digital Object Identifier

PMC9291492

Related Literature

Article Analysis
・Side Effects of cabozantinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.